Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Nations for Setting up camp - 2A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- 3Excelling at Cash The board: A Manual for Monetary Essentials
- 4Clovis Unified students spend spring break traveling through China
- 5Satellite observations offer insight into a tsunami's early stages
- Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods
- I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- 3 Must-Change Settings for iPhone Clients: Safeguard Yourself !
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- Schools to start reopening after Nigeria mass abduction
- Greece eyes migrant repatriation centres outside the EU
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
